Education
About Us
Working with TipRanks
Follow Us
Chemed Corporation (CHE)
NYSE:CHE
CHE Analyst Ratings
Moderate Buy
3 Buy
2 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
CHE Stock 12 Month Forecast
Average Price Target
$559.80
▲(23.28% Upside)
| Highest Price Target$650.00 | Average Price Target$559.80 | Lowest Price Target$480.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TR | OpenAI - 4o
$437→$480
Hold
5.71%
Upside
Reiterated
08/19/25
Oppenheimer
$650→$580
Buy
27.73%
Upside
Reiterated
07/31/25
RBC Capital
$640→$589
Buy
29.71%
Upside
Reiterated
07/31/25
Jefferies
$500
Hold
10.11%
Upside
Initiated
07/25/25
Chemed's Hold Rating: Navigating Short-Term Challenges Amid Strong Long-Term ProspectsWe initiate coverage on hospice and plumbing services provider CHE with a Hold/$500 PT. While we are big fans of CHE and the hospice space and give credit to mgmt for their track record of execution and capital allocation, the impact of recent issues related to the Medicare cap (particularly in FL) will likely carry over into '26 and limit the co's ability to achieve the Street's current '26 EBITDA growth (+12% vs our 8%) expectations, prompting our Hold. '26 Street EBITDA at Cap Issue. While we are positively-disposed on CHE's LT fundamentals, we initiate coverage with a Hold given our concern that Street ests. for '26 are too high.
Bank of America Securities
$708→$650
Buy
43.14%
Upside
Reiterated
06/30/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TR | OpenAI - 4o
$437→$480
Hold
5.71%
Upside
Reiterated
08/19/25
Oppenheimer
$650→$580
Buy
27.73%
Upside
Reiterated
07/31/25
RBC Capital
$640→$589
Buy
29.71%
Upside
Reiterated
07/31/25
Jefferies
$500
Hold
10.11%
Upside
Initiated
07/25/25
Chemed's Hold Rating: Navigating Short-Term Challenges Amid Strong Long-Term ProspectsWe initiate coverage on hospice and plumbing services provider CHE with a Hold/$500 PT. While we are big fans of CHE and the hospice space and give credit to mgmt for their track record of execution and capital allocation, the impact of recent issues related to the Medicare cap (particularly in FL) will likely carry over into '26 and limit the co's ability to achieve the Street's current '26 EBITDA growth (+12% vs our 8%) expectations, prompting our Hold. '26 Street EBITDA at Cap Issue. While we are positively-disposed on CHE's LT fundamentals, we initiate coverage with a Hold given our concern that Street ests. for '26 are too high.
Bank of America Securities
$708→$650
Buy
43.14%
Upside
Reiterated
06/30/25
Best Analysts Covering Chemed
1 Month
xxx
Success Rate
23/43 ratings generated profit
Average Return
+0.39%
reiterated a xxx
rating 23 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 53.49% of your transactions generating a profit, with an average return of +0.39% per trade.
3 Months
xxx
Success Rate
27/43 ratings generated profit
Average Return
+3.52%
reiterated a xxx
rating 23 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 62.79% of your transactions generating a profit, with an average return of +3.52% per trade.
1 Year
Success Rate
31/43 ratings generated profit
Average Return
+13.49%
reiterated a buy rating 23 days ago
Copying Michael Wiederhorn's trades and holding each position for 1 Year would result in 72.09% of your transactions generating a profit, with an average return of +13.49% per trade.
2 Years
xxx
Success Rate
28/43 ratings generated profit
Average Return
+24.76%
reiterated a xxx
rating 23 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 65.12% of your transactions generating a profit, with an average return of +24.76% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
CHE Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
0
0
0
0
0
Buy
6
9
12
11
7
Hold
3
3
3
6
8
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
9
12
15
17
15
Each month's total comprises the sum of three months' worth of ratings.
CHE Financial Forecast
CHE Stock Forecast FAQ
What is CHE’s average 12-month price target, according to analysts?
Based on analyst ratings, Chemed Corporation’s 12-month average price target is 559.80.
What is CHE’s upside potential, based on the analysts’ average price target?
Chemed Corporation has 23.28% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is CHE a Buy, Sell or Hold?
Chemed Corporation has a consensus rating of Moderate Buy which is based on 3 buy ratings, 2 hold ratings and 0 sell ratings.
What is Chemed Corporation’s price target?
The average price target for Chemed Corporation is 559.80. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $650.00 ,the lowest forecast is $480.00. The average price target represents 23.28% Increase from the current price of $454.09.
The highest analyst price target is $650.00 ,the lowest forecast is $480.00. The average price target represents 23.28% Increase from the current price of $454.09.
What do analysts say about Chemed Corporation?
Chemed Corporation’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 5 Wall Streets Analysts.
How can I buy shares of CHE?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.